Healthy Participants Clinical Trial
Official title:
A Phase I, Open-label, Single-center Relative Bioavailability and Food Effect Randomized Crossover Study of New Granule and Capsule Formulations of Selumetinib (AZD6244) in Healthy Male Subjects
This study will evaluate bioavailability and food effect of selumetinib (AZD6244) in healthy male participants. A total of 24 healthy male participants will be included to ensure at least 20 evaluable participants. The study is divided in 2 study parts; the same participants will participate in both parts of the study. Part 1 of the study is to investigate the pharmacokinetics (PK) of the selumetinib granule compared to the PK of selumetinib capsule, when administered with water under the fasted conditions. Part 2 of the study is to investigate the PK of selumetinib granule and capsule under fed conditions. Participants will also receive a single 500 mg dose of acetaminophen at the same time as selumetinib administration.
This study will be a 2-part, open-label, single-center relative bioavailability and food
effect randomized crossover study of new granule and capsule formulations of selumetinib. A
total of 24 healthy male participants aged between 18 to 45 years (inclusive), will be
included to ensure at least 20 evaluable participants. The study is divided in 2 study parts;
the same participants will participate in both parts of the study.
Part 1 of the study is designed to investigate the PK of the selumetinib granule compared to
the PK of selumetinib capsule, when administered with water under the fasted conditions. Part
2 of the study is designed to investigate the PK of selumetinib granule and capsule under fed
conditions. Participants will consume a low-fat, low-calorie meal. Thirty minutes after the
start of the meal, selumetinib will be administered to the participants. In all treatment
periods, participants will also receive a single 500 mg dose of acetaminophen at the same
time as selumetinib administration where it will act as a marker for gastric emptying. The
study will also assess the palatability of the selumetinib granule in both parts of the
study.
Each participant will receive the following treatments:
- Treatment A: 25 mg granule, fasted state
- Treatment B: 50 mg capsule, fasted state
- Treatment C: 25 mg granule, fed state
- Treatment D: 50 mg capsule, fed state Participant will be randomly assigned to 1 of 4
treatment sequences. In all cases the treatments in Part 1 will be administered before
the treatments in Part 2. The study will comprise of a screening period of maximum 28
days. Four treatment periods during which participants will be resident from the day
before dosing (Day -1) until at least 48 hours after dosing; discharged on the morning
of Day 3. A follow-up visit, will be within 7 to 10 days after the last dose of
investigational medicinal product (IMP). There will be a minimum washout period of at
least 5 days between each IMP administration. Each participant will be involved in the
study for approximately 8 to 9 weeks.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT05445440 -
A Study to Assess the Effects of BMS-986371 on the Drug Levels of Methotrexate in the Presence and Absence of Sulfasalazine
|
Phase 1 | |
| Completed |
NCT03712540 -
An Investigational Study of Experimental Medication BMS-986278 Given With the Antibiotic Rifampin in Healthy Participants
|
Phase 1 | |
| Completed |
NCT05956002 -
A Study to Evaluate the Study Medication (Etrasimod) When Mixed With Food in Healthy Participants
|
Phase 1 | |
| Completed |
NCT05539976 -
A Taste Assessment of Iberdomide and Mezigdomide in Healthy Participants
|
||
| Withdrawn |
NCT04558216 -
Evaluation of Effect of Rifampin on the Pharmacokinetics of Vonoprazan in Healthy Participants
|
Phase 1 | |
| Withdrawn |
NCT03007771 -
Magnetic Resonance-guided High-Intensity Focused Ultrasound (MR-HIFU) Used for Mild Hyperthermia
|
Phase 1 | |
| Recruiting |
NCT06097390 -
A Research Study Looking at New Protein-based Tablets in Healthy Men - Oral Formulation III
|
Phase 1 | |
| Completed |
NCT05546151 -
A Study to Assess the Safety and Tolerability of BMS-986322 in Healthy Participants of Japanese Descent
|
Phase 1 | |
| Completed |
NCT05056246 -
Study of AMG 133 Administered Subcutaneously in Healthy Japanese and Caucasian Participants
|
Phase 1 | |
| Completed |
NCT04390776 -
Bioequivalence Study of PF-06651600 Capsules Relative to Tablets and Estimation of Food Effect on Capsules.
|
Phase 1 | |
| Completed |
NCT05074459 -
A Study in Healthy Adults Investigating Eptinezumab Produced by 2 Different Manufacturing Cell Lines
|
Phase 1 | |
| Recruiting |
NCT05996250 -
Tolerance of an Immersive Virtual Reality Task Evaluating the Spatial Memory of Elderly Subjects
|
N/A | |
| Enrolling by invitation |
NCT06089109 -
Creating VIP Corps to Reduce Maternal Deaths
|
N/A | |
| Completed |
NCT03278080 -
Development of Assessment Method for Driving Ability Using Driving Simulator in Healthy Volunteers #1
|
N/A | |
| Completed |
NCT05064800 -
PF-07321332/Ritonavir and Ritonavir on Dabigatran Study in Healthy Participants
|
Phase 1 | |
| Completed |
NCT04471298 -
A Study of Qishenyiqi Dripping Pills in Healthy Participants
|
Phase 1 | |
| Completed |
NCT04914936 -
A Study to Evaluate the One-way Interaction of Calcium Carbonate, Omeprazole, or Rifampin on ACP-196
|
Phase 1 | |
| Completed |
NCT01681186 -
A Study of LY2940680 in Healthy Participants
|
Phase 1 | |
| Completed |
NCT02882386 -
Amino Acid Kinetics in Blood After Consuming Different Milk Protein Supplements
|
N/A | |
| Completed |
NCT02563262 -
Human Neutral Body Posture in Weightlessness
|
N/A |